Microbiome Therapeutics Europe, Vienna 2019

Memo

On 28-29 March 2019, leaders from across the field of microbiome therapeutics will gathering in Vienna to discuss the latest research, developments and discoveries in the pursuit to translate the power of the human microbiome into commercially viable medicines. Over 2 days, Microbiome Therapeutics Europe will explore the ins and outs of emerging technologies, learnings from clinical trials, regulatory hurdles and commercial challenges to help you gain the information and connections you need to take your pipeline to the next level. Join the likes of AOBiome, AMC Amsterdam, Merck, Eligo Bioscience, The BioCollective, BioMarketing Insight, Evolve Biosystems Inc. and more for practical industry insights, and discuss manufacturing and formulation strategies to take these projects from concepts to market. Plus, stay up-to-date of the regulatory framework developments and seek out investment opportunities to ensure you're equipped with the information you need for your products to succeed. For sponsorship and exhibition opportunities please contact This email address is being protected from spambots. You need JavaScript enabled to view it. URLs:Tickets: https://go.evvnt.com/340610-2?pid=5569 Inquiries: https://go.evvnt.com/340610-4?pid=5569  Date and Time: On Thursday March 28, 2019 at 8:00 am ends Friday March 29, 2019 at 4:20 pm Venue details: Courtyard by Marriott Vienna Prater/Messe, 4 Trabrennstraße, Wien, 1020, Austria Prices:Standard (before Friday 15th February 2019): GBP 1299.0,Academic (before Friday 15th February 2019): GBP 799.0,Standard (after Friday 15th February 2019): GBP 1499.0,Academic (after Friday 15th February 2019): GBP 899.0 Speakers: Larry Weiss, CEO and Founder at Persona Biome, Raul Cano, CSO at The BioCollective, Todd Krueger, Chief Executive Officer and President at AOBiome, Xavier Duportet, CEO at Eligo Bioscience, Regine Au, Principal at BioMarketing Insight, Michel De Baar, Executive Director, Business Development, Europe at Merck, Wouter De Jonge, Professor of NeuroGastroenterology at AMC Amsterdam, Marielle Fournier, Senior Director, Drugs, Devices and Combination Products at Voisin Consulting Life Sciences, Philippe Galant, CSO at SYNGULON, François Gianelli, Associate Director at Voisin Consulting Life Sciences, Scott Jackson, Leader - Complex Microbial Systems Group, Biosystems and Biomaterials Division at National Institute of Standards and Technology, Nikole Kimes, Founder/Vice President at Siolta Therapeutics, David Kyle, Chairman and CSO at Evolve Biosystems Inc., Daniel McDonald, Scientific Director at American Gut Project, Julian Riba, CSO at Cytena, Ricardo Valladares, Vice President, Research and Development at Siolta Therapeutics, Momo Vuyisich, Chief Science Officer at Viome, Inc